In addition, blocking proteasomal activity has been associated with decreased endothelial nitric oxide synthase (eNOS) function, resulting in diminished nitric oxide (NO) bioavailability and consequent arterial hypertension [6], which occurs in approximately 12% of patients during treatment [7]. The gene discussed is NOS3; the disease is Hypertension.